Emmaus Medical

About:

Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.

Website: http://emmausmedical.com

Twitter/X: emmauslifesci

Top Investors: Lincoln Park Capital Fund, Agility Capital

Description:

Emmaus Medical is a Torrance, California private pharmaceutical company developing and bringing to market new treatments for rare diseases and conditions. Emmaus Medical launched its first product, NutreStore [L-glutamine powder for an oral solution] for the treatment of Short Bowel Syndrome (SBS) in June 2008. The company is currently conducting a Phase 3 clinical trial to investigate the safety and efficacy of oral L-glutamine for the treatment of sickle cell disease. They are initially focusing our product development efforts on Sickle Cell Disease, a genetic disorder Emmaus Medical has received FDA orphan drug designation and fast track designation for its sickle cell treatment. The company was founded in 2000 and is headquartered in Torrance, California, United States.

Total Funding Amount:

$99.3M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Torrance, California, United States

Founded Date:

2000-01-01

Contact Email:

info(AT)emmausmedical.com

Founders:

Yutaka Niihara

Number of Employees:

51-100

Last Funding Date:

2022-06-30

IPO Status:

Public

Industries:

© 2025 bioDAO.ai